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INDEXING TERMS: PCR • single-strand conformation polymorphism • deletion mutation • missense mutation • nonsense mutation • genotype:phenotype correlation Several genetic variants of human butyrylcholine esterase (EC 3.1.1.8; BCHE) have been reported to be associated with prolonged apnea in patients given the muscle relax-ant drug succinylcholine. 4 For Ͼ30 years, serum BCHE activity, dibucaine number (DN), and fluoride number (FN) have provided sufficient information to identify most of the known BCHE phenotypes associated with succinylcholine sensitivity [1] . However, several additional BCHE variants have been discovered during the last decade, which makes phenotyping individuals very complex. The full-length BCHE cDNA of 2.4 kb has been sequenced [2, 3] ; the genomic DNA was found to be at least 73 kb long and to contain four exons interrupted by three introns at positions corresponding to nucleotides Ϫ93, 1433, and 1600 of the BCHE cDNA [4] . Moreover, the molecular basis of several genetic variants of BCHE have been reported, such as atypical gene [5] , fluoride-resistant gene [6] , silent gene [7] , K-variant [8] , J-variant [9] , and H-variant [10] . In the first report of the molecular basis of the BCHE silent gene, a frameshift mutation at Gly-117 (GGT to GGAG) was identified in two unrelated families [7] . We previously reported the genetic basis of the silent gene in four compound heterozygotes and two homozygotes in Japan [11, 12] . A decrease in serum BCHE activity is observed in hepatic disease, carcinomas, and chronic debilitating diseases [13, 14] . However, we sometimes find reduced activity without the above diseases. In this study, we wanted to determine the frequency of BCHE variants in individuals with diminished activity, and the characteristics of their laboratory data. Moreover, we investigated novel BCHE mutations and genotype:phenotype correlation and discussed the laboratory significance of serum BCHE activity around the lower limit of the reference range.
Materials and Methods subjects
Group A. Data regarding individuals deficient in serum BCHE activity (near zero) were collected from various laboratories in Japan. These individuals were definitely homozygous for silent genes as evidenced by the trace BCHE activity in serum. The laboratories found them by chance in routine laboratory tests. Secondary hypocholinesterasemia due to hepatic dysfunction was ruled out from other biochemical data (serum albumin, total cholesterol, and ␣ 2 -globulin concentration were all within normal limits) and ultrasonic imaging of the liver. The effects of organophosphorus insecticides were also ruled out from each patient's recent history. Thus, these subjects were definitely homozygous for the silent gene of BCHE.
Group B. Data regarding individuals diminished in serum BCHE activity (below the reference range of each laboratory) were collected from Seirei Health Care Center and other laboratories in which BCHE activity in serum is tested routinely. Hepatic dysfunction was also ruled out in these subjects by the criteria described above. These subjects were therefore possibly heterozygous for silent or related alleles reducing BCHE activity.
These studies were performed in accordance with the Helsinki Declaration of 1975, as revised in 1983.
measurement of serum bche activity, dibucaine number and fluoride number
Serum BCHE activity was measured by using propionylthiocholine iodide as a substrate (Aldrich, Milwaukee, WI) [15] on a Shimadzu CL-7200 biochemistry analyzer (Shimadzu, Kyoto, Japan) and calculated at 37°C. The reference range of BCHE activity was 4000 -8000 U/L. The DN and FN were also determined by the same means. DN is the percent inhibition of activity caused by 0.03 mol/L dibucaine and FN is the percent inhibition of activity caused by 4 mol/L sodium fluoride [15] .
pcr-single-strand conformation polymorphism (sscp) analysis and sequencing
Genomic DNA was extracted from EDTA-treated venous blood with the procedure of Kunkel et al. [16] . PCR-SSCP and direct sequencing procedures were performed according to our previous paper [11] . Briefly, protein-coding exons of the BCHE gene were amplified separately as nine fragments by PCR, and each amplified product was analyzed by SSCP with the Phast System (Pharmacia, Uppsala, Sweden). Amplified products displaying conformational polymophisms were directly sequenced mostly on one strand by dideoxy chain termination with Sequenase (United States Biochemical, Cleveland, OH) or by means of cycle sequencing (Taq dideoxy terminator cycle sequencing kit; ABI, Foster City, CA) with an automated DNA sequencer (ABI Model 373A).
simple method for identification of point mutations
To establish a simple method for identification for analysis of family members or suspected individuals, we developed PCR-restriction fragment length polymorphism (RFLP) assays to detect mutations affecting restriction enzyme recognition sites. For mutations that did not affect convenient restriction enzyme recognition sites, we used mismatched PCR-RFLP analysis according to our previous paper [11] . Briefly, the amplified products by mismatched PCR were digested by restriction enzymes (Toyobo, Tsuruga, Japan) for 3 h. The digests were analyzed by electrophoresis through 2% agarose gels stained with ethidium bromide.
Results

genetic mutations found in our subjects
PCR-SSCP and sequencing procedures revealed 12 kinds of genetic mutations, including 1 deletion, 9 missense, and 2 nonsense mutations ( Table 1) . One of these, designated BCHE*539T, was the K-polymorphism [8] . Five of these 12 (BCHE*FS4, *24 M, *100S, *267R, *330I) were novel mutations. The formal names of genotypes were designated as the proposed nomenclature for BCHE genetic variants [17] .
We could easily identify BCHE*24M and *100S mutations by PCR-RFLP analysis because the mutations affected the recognition sites of NlaIII and HinfI, respectively. BCHE*267R and *330I mutations did not affect recognition sites of any restriction endonucleases, and thus we developed a mismatched PCR-RFLP assay procedure. We could not design an appropriate method to confirm BCHE*FS4, but SSCP and sequencing confirmed this mutation. Table 2 shows primer sequences for PCR-RFLP with/without mismatched primer and successful annealing temperature for PCR to identify the four novel missense mutations. group a: individuals homozygous for silent genes Table 3 shows six new subjects deficient in serum BCHE activity (near zero) and six individuals published previously [11, 12] . Of the six new subjects, five were homozygous for BCHE*365R and one was homozygous for BCHE*250P. Eight of the 12 subjects were homozygous for the same mutation. BCHE*365R was the most frequent allele in this group (62.5% of total mutant alleles). Kpolymorphism was homozygously observed in 10 of 11 examined individuals.
group b: individuals diminished in serum bche activity
We analyzed 53 individuals diminished in serum BCHE activity, and found 10 mutations containing five novel mutations (four missense mutations and one deletion mutation) in 31 individuals ( Table 4 ). The K-polymorphism was observed in 13 of the remaining 22 individuals Clinical Chemistry 43, No. 6, 1997 (seven homozygous and six heterozygous). Of the total 53 individuals, 14 were homozygous for the K-polymorphism and 21 were heterozygous, representing a frequency of 49 of 104 alleles (47% as allele frequency). Some individuals showed slightly diminished DN and FN. All of these subjects had the same mutation, TTA(Leu) to ATA(Ile) at codon 330, as determined by DNA analysis.
bche activity and albumin:bche ratio in individuals heterozygous for the silent and other related genes
We collected data regarding individuals heterozygous for silent and other related genes reducing serum BCHE activity. For this purpose, we excluded the individuals initially found by diminished BCHE activity. Therefore, the target heterozygous individuals were family members detected by family analysis of individuals homozygous for silent genes. Fig. 1 shows BCHE activity and albumin: BCHE ratio. Ten of 23 individuals showed BCHE activity below the lower limit of the reference range, and 11 individuals had albumin:BCHE ratios higher than the upper limit of the reference range. BCHE activity in heterozygous individuals was significantly lower than the normal control (P Ͻ0.01), and the albumin:BCHE ratio was significantly higher (P Ͻ0.01) by Student's t-test.
Discussion
We use serum BCHE activity as an indicator of hepatic function. However, serum BCHE activity is distributed over a wide range even in healthy control subjects, which might be due to variability of genetic control of the BCHE gene. Numerous mutations have been identified as being responsible for silent genes [14, 18] . We analyzed individuals deficient or diminished in serum BCHE activity, and found 11 kinds of putative silent genes from 62 mutant alleles. Only one of these was a deletion mutation, and the others were all single-base substitutions. The deletion mutation occurred in the sequence consisting of two direct repeats; only one copy of the repeat was retained in the mutant gene. Deletion of short direct repeats could result from the slippage-mediated frame shifts during DNA replication synthesis [19] . Two of 10 mutations, BCHE*24 M and *515C, occurred at the CpG dinucleotides, well known as mutational hotspots [20] . Six of the 11 single-base substitutions, including K-polymorphism, BCHE*539T, created or interrupted a known restriction site and could be easily identified by PCR and restriction enzyme digestion. We developed a mismatched PCR method to detect the remaining five single-base substitutions that did not alter any known restriction sites. There- fore, these 11 single-base substitutions can now be easily identified.
The most frequent mutation, BCHE*365R, was found in all of the five prefectures analyzed (from north to south, Akita, Tokyo, Shizuoka, Hyogo, and Fukuoka), and four other mutations (BCHE*119STOP, *250P, *330I, and *515C) were found in two or more different prefectures. In Japan, there have been other reports of silent alleles in addition to our previous reports [11, 12] . The silent genes are BCHE*365R [21, 22] , an Alu insertion [23] , and a frameshift mutation at codon 315 [21, 24] . In the US, 12 kinds of silent genes, BCHE*FS6 (one base deletion in codon 6), *33C, *37S, *125F, *170E, *198G, *201T, *271STOP, *471R, *500STOP, *518L, and *12E3-8G (altered splicing at the acceptor site of intron 2), have been reported by La Du's laboratory [18] . The 11 silent genes we found and two other silent genes discovered in Japan are different from the mutations described by Nogueira et al. [7] and Primo-Parmo et al. [18] , discovered in the US. Therefore, there appear to be distinct ethnic differences in genetic mutations of human BCHE genes. It would thus be of interest to characterize the genetic mutations of BCHE genes from other ethnic groups. Our PCR-SSCP sequencing procedure and (or) simple identification method are convenient to screen for genetic mutations among suspected individuals.
The K-polymorphism was characterized as one of the quantitative variants (potentially causing low BCHE activity in serum) by Rubinstein et al. [25] . It was associated with a transition from guanine to adenine at nucleotide 1615, which was associated with an amino acid change from alanine 539 to threonine [8] . Among the 106 alleles of 53 individuals in group B, the frequency for the Kpolymorphism was 0.47. The frequency was significantly higher than that in a randomly selected healthy population studied previously (0.175) [26] (P Ͻ0.01 by 2 ). This seems to be because the silent genes are somewhat linked to the K-polymorphism.
Six individuals homozygous and three heterozygous for BCHE*365R (15 alleles) were homozygous for the K-polymorphism. Nine individuals heterozygous for BCHE*365R (nine alleles) were heterozygous for the K- polymorphism. The BCHE*365R, therefore, was strongly linked to the K-polymorphism (15 alleles were definitely linked and nine were possibly linked). BCHE*119STOP and *418S mutations were also found to be linked to the K-polymorphism. Our results do not suggest associations between any other mutations and the K-polymorphism. The atypical variant mutation has been reported to be linked to the K-polymorphism in European and American populations [5, 8, 25] . However, in screening for atypical genes in Japan, the atypical variant has been found to be very rare (0 of 266 hospital patients, Uchiyama et al. [27] ; 0 of 1096 hospital patients, Tanaka et al. [28] ; 1 of 1945 subjects in a population survey, Iuchi [29] ). Therefore, in the development of the BCHE gene, it seems possible that the K-polymorphism occurs first, and the point mutation in the common atypical gene, BCHE*70G [5] , or the silent gene, BCHE*365R, occurs later in each one pedigree possessing the K-polymorphism. By accumulation of data regarding individuals heterozygous for the silent gene, we could determine the effects of this mutation on serum BCHE activity. In hepatic diseases and other debilitating diseases, serum BCHE activity decreases, paralleled by reduced concentrations of serum albumin, because both BCHE and albumin are produced in the liver. We therefore plotted the albumin:BCHE ratio as well as BCHE activity. BCHE activity and the ratio were significantly different in individuals heterozygous for silent genes and healthy controls. About half of the individuals heterozygous for the silent gene showed low serum BCHE activity and higher albumin:BCHE ratio in their healthy state. We should know that the low BCHE activity state originating from genetic abnormalities is not rare in routine laboratory data, when determining serum BCHE activity exactly. 
